Adam Veness Biography and Net Worth

Joining Dianthus most recently from Cyteir Therapeutics, Mr. Veness spent much of his career as Senior Vice President, General Counsel and Secretary at Acceleron Pharma Inc. prior to the acquisition by Merck in November 2021. During his tenure at Acceleron, Mr. Veness gained experience in roles of increasing responsibility where he served on the Executive Committee responsible for company strategy, and he led all aspects of global legal and compliance, including capital markets and SEC reporting obligations, corporate governance, contracts, intellectual property, employment matters, and data privacy. Prior to moving in-house to the biotechnology industry, Mr. Veness was a corporate and securities attorney at the law firm Mintz Levin where he represented and counseled public and private companies in the biopharmaceutical, technology, and healthcare industries. Mr. Veness earned a B.A. in political science and philosophy from Tulane University, and a J.D. from Boston University School of Law.

What is Adam M. Veness' net worth?: The estimated net worth of Adam M. Veness is at least $2.47 million as of June 17th, 2026. Veness owns 30,000 shares of Dianthus Therapeutics stock worth more than $2,474,700 as of June 19th. This net worth approximation does not reflect any other investments that Veness may own. Learn More about Adam M. Veness' net worth.
How do I contact Adam M. Veness?: The corporate mailing address for Veness and other Dianthus Therapeutics executives is 203 Crescent Street, Building 17 Suite 102B, Waltham, MA 02453, United States, . Dianthus Therapeutics can also be reached via phone at 857-242-0170 and via email at [email protected]. Learn More on Adam M. Veness' contact information.
Has Adam M. Veness been buying or selling shares of Dianthus Therapeutics?: Over the course of the past ninety days, Adam M. Veness has sold $2,424,000.00 in Dianthus Therapeutics stock. Most recently, Adam M. Veness sold 30,000 shares of the business's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a transaction totalling $2,424,000.00. Following the completion of the sale, the senior vice president now directly owns 30,000 shares of the company's stock, valued at $2,424,000. Learn More on Adam M. Veness' trading history.
Who are Dianthus Therapeutics' active insiders?: Dianthus Therapeutics' insider roster includes Edward Carr (Chief Accounting Officer), Marino Garcia (President & Chief Executive Officer, Board Member), Simrat Randhawa (Insider), Ryan Savitz (CFO), and Adam Veness (SVP). Learn More on Dianthus Therapeutics' active insiders.
Are insiders buying or selling shares of Dianthus Therapeutics?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 616,089 shares worth more than $40,375,331.17. The most recent insider tranaction occured on June, 17th when SVP Adam M Veness sold 30,000 shares worth more than $2,424,000.00. Insiders at Dianthus Therapeutics own 3.0% of the company. Learn More about insider trades at Dianthus Therapeutics.
Information on this page was last updated on 6/17/2026.

Adam M. Veness Insider Trading History at Dianthus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/17/2026	Sell	30,000	$80.80	$2,424,000.00	30,000

Adam M. Veness Buying and Selling Activity at Dianthus Therapeutics

Dianthus Therapeutics Company Overview

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Today's Range

Now: $82.49

$79.79

$85.00

50 Day Range

MA: $86.74

$76.42

$95.76

2 Week Range

Now: $82.49

$16.64

$96.50

Volume

2,478,036 shs

Average Volume

967,641 shs

Market Capitalization

$4.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18